Immatics (NASDAQ:IMTX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Immatics (NASDAQ:IMTX) from a sell rating to a hold rating in a report issued on Saturday morning.

A number of other analysts have also commented on the stock. Leerink Partners reiterated an “outperform” rating and issued a $17.00 price target on shares of Immatics in a research note on Thursday, December 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immatics in a research note on Thursday, January 22nd. Guggenheim increased their price objective on shares of Immatics from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Tuesday, November 18th. Chardan Capital reiterated a “buy” rating and set a $25.00 target price on shares of Immatics in a research report on Monday, November 24th. Finally, Mizuho set a $25.00 target price on shares of Immatics in a research report on Thursday. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Immatics currently has a consensus rating of “Moderate Buy” and an average target price of $19.20.

Immatics Stock Performance

NASDAQ IMTX opened at $9.90 on Friday. Immatics has a one year low of $3.30 and a one year high of $12.41. The stock has a 50-day moving average of $9.89 and a 200 day moving average of $8.96. The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of -9.71 and a beta of 1.36.

Institutional Investors Weigh In On Immatics

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Jefferies Financial Group Inc. lifted its holdings in shares of Immatics by 323.4% during the fourth quarter. Jefferies Financial Group Inc. now owns 5,059,551 shares of the company’s stock worth $53,125,000 after purchasing an additional 3,864,636 shares during the period. RTW Investments LP raised its position in shares of Immatics by 29.7% in the fourth quarter. RTW Investments LP now owns 11,433,354 shares of the company’s stock worth $120,050,000 after acquiring an additional 2,617,737 shares during the period. T. Rowe Price Investment Management Inc. boosted its stake in shares of Immatics by 10.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 21,459,156 shares of the company’s stock worth $225,322,000 after acquiring an additional 2,075,987 shares in the last quarter. Baker BROS. Advisors LP boosted its stake in shares of Immatics by 18.9% during the 3rd quarter. Baker BROS. Advisors LP now owns 12,094,094 shares of the company’s stock worth $103,042,000 after acquiring an additional 1,925,193 shares in the last quarter. Finally, Sofinnova Investments Inc. grew its position in shares of Immatics by 54.2% during the 4th quarter. Sofinnova Investments Inc. now owns 3,435,542 shares of the company’s stock valued at $36,073,000 after acquiring an additional 1,207,705 shares during the period. 64.41% of the stock is owned by institutional investors.

About Immatics

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.